DOI:
10.1055/s-00000045
Der Nuklearmediziner
LinksClose Window
References
Pernas S, Martin M, Kaufman PA. et al.
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Lancet Oncol 2018;
19: 812-824
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.